Introduction: Financing through understanding
IP's intangible nature does little to bolster investor confidence in biotechnology. Roya Ghafele, who works as an economist at WIPO, says that biotechnology is insufficiently funded due to a lack of awareness of the value of patents among both borrowers and investors
Intangibles such as patents have historically been treated as if they were invisible, and irrelevant to individual business performance. So capital markets tended to punish research-intensive companies, which are common in biotechnology.
New growth theory explains that economic growth is...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.